Risk of major adverse cardiovascular events and all-cause mortality among patients with psoriatic disease treated with tumor necrosis factor-α and interleukin-12/23 inhibitors: a nationwide population-based cohort study in Korea

References

• Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):1–8. doi: 10.1016/S0140-6736(14)61909-7.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307. doi: 10.1111/j.1600-0625.2011.01261.x.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi: 10.1016/S0140-6736(07)61128-3.
   PubMed Web of Science ®Google Scholar
• Koch M, Baurecht H, Ried JS, et al. Psoriasis and cardiometabolic traits: modest association but distinct genetic architectures. J Invest Dermatol. 2015;135(5):1283–1293. doi: 10.1038/jid.2015.8.
   PubMed Web of Science ®Google Scholar
• Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840–848. doi: 10.1111/bjd.18245.
   PubMed Web of Science ®Google Scholar
• Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol. 2015;135(9):2189–2197. doi: 10.1038/jid.2015.87.
   PubMed Web of Science ®Google Scholar
• Bosco E, Hsueh L, Mcconeghy KW, et al. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;21(1):241. doi: 10.1186/s12874-021-01440-5.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–1741. doi: 10.1001/jama.296.14.1735.
   PubMed Web of Science ®Google Scholar
• Mcdonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med. 1973;288(17):912.
   PubMed Web of Science ®Google Scholar
• Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346. doi: 10.1038/jid.2013.149.
   PubMed Web of Science ®Google Scholar
• Cai J, Cui L, Wang Y, et al. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis. Front Pharmacol. 2021;12:774808. doi: 10.3389/fphar.2021.774808.
   PubMed Web of Science ®Google Scholar
• Caiazzo G, Fabbrocini G, Di Caprio R, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Front Immunol. 2018;9:1668. doi: 10.3389/fimmu.2018.01668.
   PubMed Web of Science ®Google Scholar
• Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130(7):1785–1796. doi: 10.1038/jid.2010.103.
   PubMed Web of Science ®Google Scholar
• Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J. 2012;33(16):1989–1991. doi: 10.1093/eurheartj/ehr425.
   PubMed Web of Science ®Google Scholar
• Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7(5):284–289. doi: 10.7150/ijms.7.284.
   PubMed Web of Science ®Google Scholar
• Terui H, Asano Y. Biologics for reducing cardiovascular risk in psoriasis patients. J Clin Med. 2023;12(3):1162. doi: 10.3390/jcm12031162.
   PubMed Web of Science ®Google Scholar
• Ham SP, Oh JH, Park HJ, et al. Validity of diagnostic codes for identification of psoriasis patients in Korea. Ann Dermatol. 2020;32(2):115–121. doi: 10.5021/ad.2020.32.2.115.
   PubMed Web of Science ®Google Scholar
• Korean Statistical Information Service. Statistics Korea. Daejeon: KOSIS; 2023.
   Google Scholar
• Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125(1):61–67. doi: 10.1111/j.0022-202X.2005.23681.x.
   PubMed Web of Science ®Google Scholar
• Padhi T, Garima. Metabolic syndrome and skin: psoriasis and beyond. Indian J Dermatol. 2013;58(4):299–305. doi: 10.4103/0019-5154.113950.
   PubMedGoogle Scholar
• Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. doi: 10.1007/s00403-006-0703-z.
   PubMed Web of Science ®Google Scholar
• Stern RS. Psoriasis is not a useful independent risk factor for cardiovascular disease. J Invest Dermatol. 2010;130(4):917–919. doi: 10.1038/jid.2009.446.
   PubMed Web of Science ®Google Scholar
• Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2010;130(4):962–967. doi: 10.1038/jid.2009.321.
   PubMed Web of Science ®Google Scholar
• Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun. 2010;2(4):325–333. doi: 10.1159/000314626.
   PubMed Web of Science ®Google Scholar
• Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206(10):2067–2077. doi: 10.1084/jem.20090545.
   PubMed Web of Science ®Google Scholar
• Erbel C, Dengler TJ, Wangler S, et al. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res Cardiol. 2011;106(1):125–134. doi: 10.1007/s00395-010-0135-y.
   PubMed Web of Science ®Google Scholar
• Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577. doi: 10.1093/eurheartj/ehs263.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–1134. doi: 10.1111/jdv.12768.
   PubMed Web of Science ®Google Scholar
• Hong JR, Jeong H, Kim H, et al. The potential impact of systemic anti-inflammatory therapies in psoriasis on major adverse cardiovascular events: a Korean nationwide cohort study. Sci Rep. 2021;11(1):8588. doi: 10.1038/s41598-021-87766-y.
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489. doi: 10.1136/annrheumdis-2014-206624.
   PubMed Web of Science ®Google Scholar
• Yang ZS, Lin NN, Li L, et al. The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol. 2016;51(2):240–247. doi: 10.1007/s12016-016-8560-9.
   PubMed Web of Science ®Google Scholar
• Rungapiromnan W, Yiu ZZN, Warren RB, et al. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890–901. doi: 10.1111/bjd.14964.
   PubMed Web of Science ®Google Scholar
• Karpouzas GA, Ormseth SR, Hernandez E, et al. Biologics may prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high-risk lesions. Arthritis Rheumatol. 2020;72(9):1467–1475. doi: 10.1002/art.41293.
   PubMed Web of Science ®Google Scholar
• Ozen G, Pedro S, Michaud K. The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 2021;48(5):648–655. doi: 10.3899/jrheum.200265.
   PubMed Web of Science ®Google Scholar
• Beinsberger J, Heemskerk JW, Cosemans JM. Chronic arthritis and cardiovascular disease: altered blood parameters give rise to a prothrombotic propensity. Semin Arthritis Rheum. 2014;44(3):345–352. doi: 10.1016/j.semarthrit.2014.06.006.
   PubMed Web of Science ®Google Scholar
• Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease. Arthritis Rheumatol. 2018;70(3):408–416. doi: 10.1002/art.40366.
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. doi: 10.1016/j.jaad.2018.06.057.
   PubMed Web of Science ®Google Scholar
• Di Minno MN, Iervolino S, Peluso R, et al. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-alpha blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31(3):705–712. doi: 10.1161/ATVBAHA.110.214585.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200–207. doi: 10.1001/archdermatol.2007.63.
   PubMedGoogle Scholar
• Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304–314. doi: 10.1038/jid.2011.304.
   PubMed Web of Science ®Google Scholar
• Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862–872. doi: 10.1111/j.1365-2133.2011.10257.x.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–871. doi: 10.1001/jama.2011.1211.
   PubMed Web of Science ®Google Scholar
• Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013;27(5):622–627. doi: 10.1111/j.1468-3083.2012.04500.x.
   PubMed Web of Science ®Google Scholar
• Choi H, Uceda DE, Dey AK, et al. Treatment of psoriasis with biologic therapy is associated with improvement of coronary artery plaque lipid-rich necrotic core: results from a prospective, observational study. Circ Cardiovasc Imaging. 2020;13:e011199.
   PubMed Web of Science ®Google Scholar
• Poizeau F, Nowak E, Kerbrat S, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12/23p40 antibody ustekinumab. JAMA Dermatol. 2020;156(11):1208–1215. doi: 10.1001/jamadermatol.2020.2977.
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Libby P, Tedgui A. Anticytokine immune therapy and atherothrombotic cardiovascular risk. Arterioscler Thromb Vasc Biol. 2019;39(8):1510–1519. doi: 10.1161/ATVBAHA.119.311998.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013;27(12):1535–1545. doi: 10.1111/jdv.12046.
   PubMed Web of Science ®Google Scholar
• Gelfand JM. Commentary: does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality: a critical question that we are only just beginning to answer. J Am Acad Dermatol. 2018;79(1):69–70. doi: 10.1016/j.jaad.2018.03.046.
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Papadavid E, Makavos G, et al. Lowering interleukin-12 activity improves myocardial and vascular function compared with tumor necrosis factor-a antagonism or cyclosporine in psoriasis. Circ Cardiovasc Imaging. 2017;10(9):e006283. doi: 10.1161/CIRCIMAGING.117.006283.
   PubMed Web of Science ®Google Scholar
• Pina Vegas L, Le Corvoisier P, Penso L, et al. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology (Oxford). 2022;61(4):1589–1599. doi: 10.1093/rheumatology/keab522.
   PubMed Web of Science ®Google Scholar
• Lee MP, Desai RJ, Jin Y, et al. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol. 2019;155(6):700–707. doi: 10.1001/jamadermatol.2019.0001.
   PubMed Web of Science ®Google Scholar
• Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: feasibility study using (18)F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol. 2019;80(5):1322–1331. doi: 10.1016/j.jaad.2018.03.011.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Bøttcher M, Vestergaard C, et al. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152(10):1114–1121. doi: 10.1001/jamadermatol.2016.1984.
   PubMed Web of Science ®Google Scholar